Hydroxyurea is an oral medication that is beneficial for reducing the complications of sickle cell disease, but it must be taken every day to be effective. Nancy Green, MD, is studying the differences among patients in their response to this drug: the genetics of response to hydroxyurea, their adherence to therapy, and cultural and other aspects which may influence their use of the drug. She is leading the HABIT study (Hydroxyurea Adherence for Personal Best in Sickle Cell Treatment), which is assessing an intervention using community health worker support to address existing barriers to improve the use of hydroxyurea, augmented by daily text message reminders to parents and youths.

Interested in referring a patient for the study? Contact (212) 305-0494.